Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$0.57 -0.9%	$0.51	$0.34 ▼ $3.46	$49.47M	1.8	473,756 shs	421,442 shs
SOPH SOPHiA GENETICS	$2.89 -1.4%	$3.02	$2.58 ▼ $6.28	$192.73M	1.03	61,323 shs	20,208 shs
VYGR Voyager Therapeutics	$2.99 -5.1%	$3.37	$2.75 ▼ $9.55	$174.31M	0.95	442,228 shs	342,931 shs
YMAB Y-mAbs Therapeutics	$4.13 +0.7%	$4.42	$3.55 ▼ $16.11	$187.02M	0.53	311,468 shs	94,643 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	-0.93%	+10.98%	+6.33%	-21.34%	-82.60%
SOPH SOPHiA GENETICS	-1.37%	-7.07%	-0.69%	-28.99%	-38.51%
VYGR Voyager Therapeutics	-5.08%	-8.84%	-11.28%	-29.15%	-63.98%
YMAB Y-mAbs Therapeutics	+0.73%	+6.99%	-3.05%	-27.80%	-67.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IPSC Century Therapeutics	2.4571 of 5 stars	3.5	3.0	0.0	2.4	1.7	0.6
SOPH SOPHiA GENETICS	1.7709 of 5 stars	3.4	5.0	0.0	0.0	0.0	0.6
VYGR Voyager Therapeutics	4.663 of 5 stars	4.6	2.0	4.6	2.1	1.7	1.9
YMAB Y-mAbs Therapeutics	3.4392 of 5 stars	4.4	1.0	0.0	3.0	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPSC Century Therapeutics	3.00	Buy	$4.20	631.45% Upside
SOPH SOPHiA GENETICS	2.75	Moderate Buy	$6.80	135.29% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	347.83% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$16.60	301.94% Upside

Current Analyst Ratings Breakdown

Latest IPSC, SOPH, VYGR, and YMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
3/28/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/24/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $7.00
3/21/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/21/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $12.00

(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSC Century Therapeutics	$114.90M	0.43	N/A	N/A	$3.06 per share	0.19
SOPH SOPHiA GENETICS	$67.17M	2.87	N/A	N/A	N/A	∞
VYGR Voyager Therapeutics	$66.96M	2.47	$2.12 per share	1.41	$5.37 per share	0.56
YMAB Y-mAbs Therapeutics	$87.69M	2.13	N/A	N/A	$2.32 per share	1.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSC Century Therapeutics	-$136.67M	-$0.29	N/A	N/A	N/A	-4,837.73%	-61.66%	-31.78%	N/A
SOPH SOPHiA GENETICS	-$78.98M	-$1.00	N/A	N/A	N/A	-110.71%	-55.06%	-38.33%	8/5/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.21	N/A	N/A	15.80%	8.33%	6.15%	8/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.64	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	8/11/2025 (Estimated)

Latest IPSC, SOPH, VYGR, and YMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/6/2025	Q1 2025	SOPH SOPHiA GENETICS	-$0.21	-$0.26	-$0.05	-$0.26	$16.76 million	$17.78 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
3/19/2025	Q4 2024	IPSC Century Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	$0.67 million	$4.18 million
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million
3/4/2025	Q4 2024	SOPH SOPHiA GENETICS	-$0.23	-$0.23	N/A	-$0.23	$17.71 million	$17.73 million
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSC Century Therapeutics	N/A	10.39	10.39
SOPH SOPHiA GENETICS	0.12	3.80	3.59
VYGR Voyager Therapeutics	N/A	8.45	8.45
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSC Century Therapeutics	50.20%
SOPH SOPHiA GENETICS	31.59%
VYGR Voyager Therapeutics	48.03%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
IPSC Century Therapeutics	6.80%
SOPH SOPHiA GENETICS	4.88%
VYGR Voyager Therapeutics	6.39%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSC Century Therapeutics	170	86.16 million	79.25 million	Optionable
SOPH SOPHiA GENETICS	520	66.69 million	62.19 million	Not Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.15 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

IPSC, SOPH, VYGR, and YMAB Headlines

Recent News About These Companies

HC Wainwright Brokers Reduce Earnings Estimates for YMAB

May 23 at 1:39 AM | americanbankingnews.com

FY2026 Earnings Forecast for YMAB Issued By HC Wainwright

May 22 at 7:40 AM | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright

May 21 at 8:15 AM | marketbeat.com

D. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 20 at 4:10 AM | marketbeat.com

HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $11.00

May 20 at 1:45 AM | americanbankingnews.com

YMAB FY2025 EPS Forecast Raised by Cantor Fitzgerald

May 18, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.70 Consensus Target Price from Analysts

May 18, 2025 | americanbankingnews.com

Wedbush Cuts Earnings Estimates for Y-mAbs Therapeutics

May 17, 2025 | marketbeat.com

Wedbush Forecasts Reduced Earnings for Y-mAbs Therapeutics

May 17, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Brokerages

May 17, 2025 | marketbeat.com

Truist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $14.00

May 17, 2025 | americanbankingnews.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Paradigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 16, 2025 | marketbeat.com

Oppenheimer Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $20.00

May 16, 2025 | americanbankingnews.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13, 2025 | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | globenewswire.com

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SOPH, VYGR, and YMAB Company Descriptions

Century Therapeutics NASDAQ:IPSC

$0.57 -0.01 (-0.93%)

Closing price 05/22/2025 04:00 PM Eastern

Extended Trading

$0.55 -0.03 (-4.74%)

As of 05/22/2025 05:47 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

SOPHiA GENETICS NASDAQ:SOPH

$2.89 -0.04 (-1.37%)

Closing price 05/22/2025 04:00 PM Eastern

Extended Trading

$2.88 -0.01 (-0.35%)

As of 05/22/2025 04:31 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Voyager Therapeutics NASDAQ:VYGR

$2.99 -0.16 (-5.08%)

Closing price 05/22/2025 04:00 PM Eastern

Extended Trading

$3.04 +0.04 (+1.51%)

As of 05/22/2025 07:57 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.13 +0.03 (+0.73%)

Closing price 05/22/2025 04:00 PM Eastern

Extended Trading

$4.13 0.00 (0.00%)

As of 05/22/2025 06:13 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time